Journal
ANNALS OF HEMATOLOGY
Volume 88, Issue 4, Pages 347-350Publisher
SPRINGER
DOI: 10.1007/s00277-008-0600-y
Keywords
Amyloidosis; Melphalan; Dexamethasone; Thalidomide; Response
Categories
Funding
- Collegio Ghislieri, Pavia, Italy
- European Community Sixth Framework Program
Ask authors/readers for more resources
Patients with primary (AL) amyloidosis and heart failure have a very poor prognosis and cannot tolerate aggressive therapy, such as autologous stem cell transplantation and high-dose dexamethasone-based regimens. We prospectively treated 22 patients with advanced cardiac amyloidosis combining oral melphalan, thalidomide, and reduced intensity dexamethasone (MTD). Six patients died due to cardiac amyloidosis before completing cycle 3. Early death was associated with reduced ejection fraction. Eight patients achieved a hematological response and four achieved a durable improvement of cardiac dysfunction. Treatment with MTD is feasible in patients with advanced cardiac AL amyloidosis and effective in subjects with preserved systolic function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available